Melatonin does not prevent the protection of ischemic preconditioning in vivo despite its antioxidant effect against oxidative stress.
Free radicals are involved in the protective mechanism of preconditioning (PC), whereas antioxidant compounds abolish this benefit. Melatonin is a hormone with antioxidant properties. The aim of our study was to evaluate the effect of melatonin on infarct size in ischemic preconditioning in vivo. We randomly divided 33 male rabbits into four groups and subjected them to 30 min of myocardial ischemia and 3 h of reperfusion with the following prior interventions: (i) no intervention, (ii) iv melatonin at a total dose of 50 mg/kg, (iii) PC with two cycles of 5 min ischemia and 10 min reperfusion, and (iv) combined melatonin and PC. In a second series of experiments, another antioxidant agent N-acetylcysteine (NAC) was used in a control and in a PC group. Myocardial infarct size was determined and blood samples were drawn at different time points for the determination of lipid peroxidation products, total superoxide dismutase (SOD) activity, and (1)H-NMR spectra to evaluate the changes in the metabolic profile. Melatonin showed no effect on myocardial infarct size in the group of sustained ischemia (42.9 +/- 3.6% vs 47.4 +/- 4.9%) and it did not attenuate the reduction of myocardial infarct size in the PC group (13.6 +/- 2.4% vs 14.0 +/- 1.7%). A similar effect was found in NAC-treated groups (44.8 +/- 3.4% vs 14.3 +/- 1.3%). Lipid peroxidation product levels were significantly elevated in the control and PC groups, whereas melatonin decreased them in both groups. The SOD activity was enhanced in the PC group compared to controls; melatonin kept SOD activity unchanged during ischemia/reperfusion and enhanced its activity when it was combined with PC. Melatonin did not change the metabolic profile of the control and PC groups. Melatonin does not prevent the beneficial effect of ischemic PC on infarct size despite its antioxidant properties.
Andreadou
Ioanna
I
Second Department of Cardiology, Onassis Cardiac Surgery Center, Athens, Greece. ioannandread@yahoo.com
Iliodromitis
Efstathios K
EK
Mikros
Emmanuel
E
Bofilis
Elias
E
Zoga
Anastasia
A
Constantinou
Maria
M
Tsantili-Kakoulidou
Anna
A
Kremastinos
Dimitrios T
DT
D000111:Acetylcysteine / Q000737:chemistry / Q000494:pharmacology; D000447:Aldehydes / Q000494:pharmacology; D000818:Animals; D000975:Antioxidants / Q000378:metabolism / Q000494:pharmacology*; D005609:Free Radicals; D019194:Ischemic Preconditioning; D015227:Lipid Peroxidation; D009682:Magnetic Resonance Spectroscopy; D008297:Male; D008315:Malondialdehyde / Q000494:pharmacology; D008550:Melatonin / Q000378:metabolism*; D015233:Models, Statistical; D018384:Oxidative Stress; D011817:Rabbits; D015427:Reperfusion Injury; D013482:Superoxide Dismutase / Q000378:metabolism; D013997:Time Factors
D000447:Aldehydes; D000975:Antioxidants; D005609:Free Radicals; D008315:Malondialdehyde; D013482:Superoxide Dismutase; D008550:Melatonin; C027576:4-hydroxy-2-nonenal; D000111:Acetylcysteine